NASDAQ:HZNP - Horizon Therapeutics Public Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $111.36
  • Forecasted Upside: 20.86 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$92.14
▲ +1.24 (1.36%)
1 month | 3 months | 12 months
Get New Horizon Therapeutics Public Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HZNP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HZNP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$111.36
▲ +20.86% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Horizon Therapeutics Public in the last 3 months. The average price target is $111.36, with a high forecast of $125.00 and a low forecast of $90.00. The average price target represents a 20.86% upside from the last price of $92.14.

Buy

The current consensus among 12 contributing investment analysts is to buy stock in Horizon Therapeutics Public. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/25/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/24/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/22/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/20/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/27/2021Maxim GroupReiterated RatingReduceHigh
i
3/29/2021Morgan StanleyReiterated RatingOverweight$103.00High
i
3/25/2021GuggenheimBoost Price TargetBuy$115.00 ➝ $120.00Low
i
3/22/2021Morgan StanleyInitiated CoverageOverweight$103.00Medium
i
3/19/2021Jefferies Financial GroupReiterated RatingBuy$120.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/18/2021CitigroupBoost Price Target$116.00 ➝ $120.00High
i
3/18/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated RatingBuy$120.00High
i
3/17/2021Stifel NicolausBoost Price TargetBuy$110.00 ➝ $125.00High
i
3/11/2021Wolfe ResearchInitiated CoverageOutperform$107.00Low
i
2/17/2021Jefferies Financial GroupBoost Price Target$103.00 ➝ $120.00Low
i
2/9/2021Bank of AmericaReiterated RatingBuy$100.00Low
i
Rating by Jason Gerberry at Bank of America Co.
11/3/2020BMO Capital MarketsBoost Price TargetOutperform$105.00 ➝ $110.00Medium
i
9/9/2020JPMorgan Chase & Co.Initiated CoverageOverweight$110.00High
i
8/27/2020CitigroupInitiated CoverageBuy$112.00Medium
i
8/17/2020Bank of AmericaBoost Price TargetBuy$92.00 ➝ $95.00Low
i
Rating by Jason Gerberry at Bank of America Co.
8/10/2020Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $90.00Low
i
8/6/2020GuggenheimBoost Price Target$64.00 ➝ $100.00High
i
8/6/2020BMO Capital MarketsBoost Price TargetOutperform$70.00 ➝ $105.00High
i
8/3/2020Stifel NicolausBoost Price Target$60.00 ➝ $85.00Low
i
Rating by Annabel Samimy at Stifel Nicolaus
7/31/2020Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $70.00Low
i
7/22/2020Piper SandlerBoost Price TargetOverweight$61.00 ➝ $90.00Low
i
Rating by David Amsellem at Piper Sandler
7/16/2020GuggenheimBoost Price Target$50.00 ➝ $64.00Low
i
6/5/2020Piper SandlerReiterated RatingBuy$61.00Medium
i
Rating by David Amsellem at Piper Sandler
5/29/2020Stifel NicolausBoost Price Target$50.00 ➝ $60.00High
i
Rating by Annabel Samimy at Stifel Nicolaus
5/26/2020Bank of AmericaBoost Price TargetBuy$52.00 ➝ $57.00Medium
i
Rating by Jason Gerberry at Bank of America Co.
5/21/2020Piper SandlerBoost Price TargetOverweight$50.00 ➝ $61.00Medium
i
5/8/2020Morgan StanleyBoost Price TargetOverweight$39.00 ➝ $50.00High
i
4/28/2020Jefferies Financial GroupBoost Price TargetBuy$47.00 ➝ $51.00High
i
4/14/2020Piper SandlerLower Price TargetOverweight$46.00 ➝ $44.00High
i
4/8/2020Stifel NicolausReiterated RatingBuy$45.00Low
i
Rating by Annabel Samimy at Stifel Nicolaus
4/2/2020Morgan StanleyLower Price TargetOverweight$42.00 ➝ $39.00High
i
3/23/2020Bank of AmericaLower Price TargetBuy$45.00 ➝ $42.00Low
i
Rating by Jason Gerberry at Bank of America Co.
2/25/2020Bank of AmericaReiterated RatingBuy$45.00High
i
Rating by Jason Gerberry at Bank of America Co.
1/22/2020BMO Capital MarketsBoost Price TargetOutperform$40.00 ➝ $46.00Low
i
1/14/2020JMP SecuritiesBoost Price TargetOutperform$47.00Medium
i
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$35.00Low
i
12/24/2019Piper Jaffray CompaniesReiterated RatingBuy$36.00 ➝ $49.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
12/16/2019Morgan StanleyBoost Price TargetOverweight$32.00 ➝ $38.00High
i
12/16/2019Jefferies Financial GroupBoost Price TargetBuy$35.00 ➝ $40.00High
i
12/16/2019Stifel NicolausBoost Price TargetBuy$35.00 ➝ $40.00High
i
Rating by Annabel Samimy at Stifel Nicolaus
12/16/2019BMO Capital MarketsBoost Price TargetOutperform$36.00 ➝ $40.00High
i
11/8/2019Cantor FitzgeraldBoost Price TargetOverweight$32.00 ➝ $36.00Low
i
9/26/2019Bank of AmericaInitiated CoverageBuy$34.00High
i
9/13/2019Stifel NicolausSet Price TargetBuy$35.00Low
i
Rating by Annabel Samimy at Stifel Nicolaus
9/12/2019GuggenheimInitiated CoverageBuy$36.00Low
i
8/26/2019Piper Jaffray CompaniesSet Price TargetBuy$33.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
8/14/2019BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$29.00 ➝ $36.00Low
i
Rating by Gary Nachman at BMO Capital Markets
8/7/2019CowenSet Price TargetBuy$35.00Medium
i
Rating by Ken Cacciatore at Cowen Inc
5/8/2019MizuhoSet Price TargetHold$27.00Low
i
Rating by Irina Rivkind Koffler at Mizuho
5/1/2019CitigroupUpgradeNeutral ➝ Buy$21.00 ➝ $32.00Medium
i
4/4/2019Piper Jaffray CompaniesSet Price TargetBuy$33.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
4/4/2019BMO Capital MarketsBoost Price TargetMarket Perform$29.00Medium
i
4/2/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Buy$26.00 ➝ $32.00Medium
i
3/8/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$32.00Low
i
3/1/2019JMP SecuritiesBoost Price TargetOutperform$26.00 ➝ $38.00High
i
Rating by Donald Ellis at JMP Securities
3/1/2019Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$34.00High
i
3/1/2019MizuhoReiterated RatingPositive ➝ Neutral$27.00High
i
2/28/2019CowenSet Price TargetBuy$33.00Medium
i
Rating by Ken Cacciatore at Cowen Inc
2/7/2019MizuhoReiterated RatingHold$21.00Low
i
1/14/2019Piper Jaffray CompaniesSet Price TargetBuy$26.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
11/15/2018MizuhoDowngradeBuy ➝ Neutral$25.00 ➝ $21.00High
i
11/7/2018MizuhoReiterated RatingBuy$25.00High
i
11/1/2018Stifel NicolausBoost Price TargetBuy$25.00 ➝ $35.00High
i
10/23/2018CowenSet Price TargetBuy$25.00High
i
Rating by Ken Cacciatore at Cowen Inc
10/18/2018Cantor FitzgeraldReiterated RatingBuy$21.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
10/16/2018MizuhoReiterated RatingBuyHigh
i
10/6/2018JMP SecuritiesSet Price TargetBuy$22.00High
i
Rating by Donald Ellis at JMP Securities
10/4/2018The Goldman Sachs GroupSet Price TargetBuy$26.00Low
i
Rating by Dana Flanders at The Goldman Sachs Group, Inc.
9/24/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
9/17/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00High
i
Rating by David Amsellem at Piper Jaffray Companies
9/13/2018Cantor FitzgeraldReiterated RatingBuy$21.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/17/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $24.00Low
i
8/9/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$21.00 ➝ $23.00High
i
8/9/2018CowenReiterated RatingBuy$25.00High
i
8/9/2018Piper Jaffray CompaniesReiterated RatingBuy$25.00High
i
8/8/2018MizuhoReiterated RatingBuy$18.00High
i
8/8/2018Cantor FitzgeraldSet Price TargetBuy$21.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/6/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$18.00 ➝ $18.00Low
i
7/25/2018Cantor FitzgeraldBoost Price TargetOverweight$21.00High
i
Rating by Louise Chen at Cantor Fitzgerald
6/27/2018CitigroupDowngradeBuy ➝ NeutralLow
i
6/18/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.00Low
i
5/9/2018Cantor FitzgeraldSet Price TargetBuy$17.00High
i
Rating by Louise Chen at Cantor Fitzgerald
5/7/2018MizuhoReiterated RatingBuy$18.00Low
i
4/15/2018Cantor FitzgeraldSet Price TargetBuy$17.00High
i
Rating by Louise Chen at Cantor Fitzgerald
3/14/2018Cantor FitzgeraldReiterated RatingBuy$17.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
3/2/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $16.00High
i
3/1/2018Piper Jaffray CompaniesReiterated RatingBuy$22.00High
i
Rating by David Amsellem at Piper Jaffray Companies
3/1/2018CowenReiterated RatingBuy$24.00High
i
3/1/2018UBS GroupSet Price TargetBuy$20.00Medium
i
Rating by Marc Goodman at UBS Group AG
2/28/2018Cantor FitzgeraldSet Price TargetBuy$17.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
1/12/2018MizuhoUpgradeNeutral ➝ Buy$12.00 ➝ $18.00Medium
i
1/8/2018Cantor FitzgeraldSet Price TargetBuy$17.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
12/27/2017Cantor FitzgeraldSet Price TargetBuy$17.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
12/1/2017Cantor FitzgeraldSet Price TargetBuy$17.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
11/30/2017UBS GroupSet Price TargetBuy$16.00 ➝ $20.00High
i
Rating by Marc Goodman at UBS Group AG
11/7/2017Jefferies Financial GroupBoost Price TargetBuy$16.00 ➝ $21.00N/A
i
10/22/2017Stifel NicolausReiterated RatingBuy$20.00N/A
i
Rating by Annabel Samimy at Stifel Nicolaus
10/15/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
10/5/2017Jefferies Financial GroupReiterated RatingBuy$16.00N/A
i
Rating by David Steinberg at Jefferies Financial Group Inc.
9/28/2017CowenReiterated RatingBuyLow
i
Rating by Ken Cacciatore at Cowen Inc
9/28/2017The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$16.00Medium
i
9/27/2017Jefferies Financial GroupReiterated RatingBuy$16.00Medium
i
Rating by David Steinberg at Jefferies Financial Group Inc.
9/26/2017Cantor FitzgeraldReiterated RatingBuy$17.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
9/11/2017Cantor FitzgeraldReiterated RatingBuy$17.00High
i
Rating by Louise Chen at Cantor Fitzgerald
9/10/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
8/28/2017MizuhoReiterated RatingHold$9.00 ➝ $12.00Medium
i
8/17/2017Cantor FitzgeraldSet Price TargetBuy$17.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
8/10/2017BMO Capital MarketsReiterated RatingOutperform$17.00 ➝ $18.00High
i
8/9/2017Cantor FitzgeraldReiterated RatingOverweight$13.00 ➝ $17.00High
i
Rating by Louise Chen at Cantor Fitzgerald
8/9/2017MizuhoReiterated RatingNeutral$10.00 ➝ $9.00Low
i
8/8/2017UBS GroupSet Price TargetBuy$16.00High
i
Rating by Marc Goodman at UBS Group AG
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00High
i
Rating by David Amsellem at Piper Jaffray Companies
7/31/2017Cantor FitzgeraldSet Price TargetBuy$13.00High
i
7/28/2017BMO Capital MarketsReiterated RatingBuy$17.00High
i
7/25/2017Piper Jaffray CompaniesSet Price TargetBuy$17.00High
i
Rating by David Amsellem at Piper Jaffray Companies
7/14/2017Jefferies Financial GroupReiterated RatingBuy$14.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$13.00Low
i
6/7/2017UBS GroupSet Price TargetBuy$22.00 ➝ $16.00N/A
i
Rating by Marc Goodman at UBS Group AG
5/9/2017CitigroupLower Price TargetBuy$20.00 ➝ $13.00Medium
i
5/9/2017Jefferies Financial GroupSet Price TargetBuy$26.00 ➝ $14.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
5/9/2017Stifel NicolausReiterated RatingBuy ➝ Buy$35.00 ➝ $20.00High
i
5/9/2017CowenSet Price TargetOutperform$42.00 ➝ $20.00Medium
i
5/9/2017MizuhoDowngradeBuy ➝ Neutral$22.00 ➝ $10.00High
i
5/9/2017BMO Capital MarketsReiterated RatingBuy$24.00 ➝ $17.00High
i
Rating by Gary Nachman at BMO Capital Markets
4/12/2017Jefferies Financial GroupSet Price TargetBuy$26.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/29/2017BMO Capital MarketsReiterated RatingBuy$24.00Low
i
Rating by Gary Nachman at BMO Capital Markets
3/24/2017Piper Jaffray CompaniesLower Price TargetOverweight$32.00 ➝ $30.00Low
i
2/28/2017MizuhoLower Price TargetBuy ➝ Buy$25.00 ➝ $22.00N/A
i
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/A
i
Rating by david risinger at Morgan Stanley
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/A
i
2/22/2017MizuhoReiterated RatingBuy$25.00N/A
i
12/18/2016Jefferies Financial GroupSet Price TargetBuy$26.00N/A
i
Rating by David Steinberg at Jefferies Financial Group Inc.
12/16/2016MizuhoUpgradeNeutral ➝ Buy$14.00 ➝ $25.00N/A
i
12/9/2016MizuhoDowngradeBuy ➝ Neutral$30.00 ➝ $14.00N/A
i
12/8/2016UBS GroupSet Price TargetBuy$23.00N/A
i
Rating by Marc Goodman at UBS Group AG
12/8/2016Jefferies Financial GroupSet Price TargetBuy$26.00N/A
i
Rating by David Steinberg at Jefferies Financial Group Inc.
12/8/2016BMO Capital MarketsReiterated RatingOutperform$29.00 ➝ $24.00N/A
i
12/1/2016MizuhoReiterated RatingBuyN/A
i
11/28/2016BMO Capital MarketsReiterated RatingOutperform$29.00N/A
i
11/28/2016CitigroupUpgradeNeutral ➝ BuyN/A
i
11/8/2016MizuhoBoost Price TargetBuy$29.00 ➝ $30.00N/A
i
10/31/2016MizuhoLower Price TargetBuy$33.00 ➝ $29.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
10/12/2016The Goldman Sachs GroupSet Price TargetBuy$26.00N/A
i
Rating by Stephan Stewart at The Goldman Sachs Group, Inc.
10/11/2016MizuhoReiterated RatingBuy$33.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/29/2016MizuhoReiterated RatingBuyN/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/28/2016Morgan StanleyReiterated RatingHold$24.00N/A
i
Rating by david risinger at Morgan Stanley
9/27/2016The Goldman Sachs GroupReiterated RatingBuy$27.00N/A
i
9/13/2016BMO Capital MarketsReiterated RatingOutperform$30.00N/A
i
9/13/2016MizuhoBoost Price TargetBuy$30.00 ➝ $33.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/12/2016Morgan StanleySet Price TargetHold$24.00N/A
i
Rating by david risinger at Morgan Stanley
9/12/2016Brean CapitalReiterated RatingBuy$32.00N/A
i
Rating by Difei Yang at Brean Capital
9/12/2016CowenReiterated RatingOutperform ➝ Outperform$42.00N/A
i
Rating by Ken Cacciatore at Cowen Inc
9/8/2016The Goldman Sachs GroupReiterated RatingBuy$27.00N/A
i
9/8/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by david steinberg at Jefferies Financial Group Inc.
8/23/2016GuggenheimReiterated RatingBuy$30.00N/A
i
Rating by Louise Chen at Guggenheim
8/10/2016MizuhoReiterated RatingBuy$24.00 ➝ $30.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
8/10/2016BMO Capital MarketsReiterated RatingOutperform$29.00 ➝ $30.00N/A
i
8/10/2016Piper Jaffray CompaniesReiterated RatingOverweight$34.00 ➝ $33.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
8/9/2016Brean CapitalReiterated RatingBuy$30.00N/A
i
Rating by Difei Yang at Brean Capital
8/9/2016CitigroupBoost Price TargetNeutral$18.00 ➝ $21.00N/A
i
8/9/2016UBS GroupReiterated RatingBuy$24.00N/A
i
Rating by Marc Goodman at UBS Group AG
8/4/2016Jefferies Financial GroupReiterated RatingBuy$27.00N/A
i
Rating by David Steinberg at Jefferies Financial Group Inc.
8/3/2016BMO Capital MarketsReiterated RatingOutperform$29.00N/A
i
8/3/2016MizuhoReiterated RatingOutperform$24.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
8/2/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Difei Yang at Brean Capital
8/1/2016GuggenheimReiterated RatingBuy$30.00N/A
i
7/14/2016Brean CapitalReiterated RatingBuy$30.00N/A
i
Rating by Difei Yang at Brean Capital
7/11/2016Morgan StanleyUpgradeUnderweight ➝ Equal Weight$24.00N/A
i
7/6/2016Stifel NicolausReiterated RatingBuy$45.00N/A
i
Rating by Annabel Samimy at Stifel Nicolaus
6/28/2016BMO Capital MarketsInitiated CoverageOutperform$29.00N/A
i
(Data available from 6/17/2016 forward)
Horizon Therapeutics Public logo
Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $92.14
$89.63
$92.42

50 Day Range

MA: $91.73
$86.24
$95.75

52 Week Range

Now: $92.14
$47.97
$97.36

Volume

2,036,892 shs

Average Volume

1,769,320 shs

Market Capitalization

$20.71 billion

P/E Ratio

79.43

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?

The following Wall Street analysts have issued reports on Horizon Therapeutics Public in the last twelve months: Bank of America Co., BMO Capital Markets, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Piper Sandler, Stifel Nicolaus, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for HZNP.

What is the current price target for Horizon Therapeutics Public?

11 Wall Street analysts have set twelve-month price targets for Horizon Therapeutics Public in the last year. Their average twelve-month price target is $111.36, suggesting a possible upside of 22.5%. Stifel Nicolaus has the highest price target set, predicting HZNP will reach $125.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $90.00 for Horizon Therapeutics Public in the next year.
View the latest price targets for HZNP.

What is the current consensus analyst rating for Horizon Therapeutics Public?

Horizon Therapeutics Public currently has 1 sell rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HZNP will outperform the market and that investors should add to their positions of Horizon Therapeutics Public.
View the latest ratings for HZNP.

What other companies compete with Horizon Therapeutics Public?

How do I contact Horizon Therapeutics Public's investor relations team?

Horizon Therapeutics Public's physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company's listed phone number is 011-353-1772-2100 and its investor relations email address is [email protected] The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.